Navidea Biopharmaceuticals Reports Second Quarter and Year-to-Date 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Navidea Biopharma (NAVB) Reports Q2 Loss of $0.11, Revenues Beat
August 13, 2020 4:32 PM EDTNavidea Biopharma (NYSE: NAVB) reported Q2 EPS of ($0.11), versus ($0.24) reported last year. Revenue for the quarter came in at $271 thousand versus the consensus estimate of $156 thousand.
The past four months have been truly momentous for the company. The successful second interim look... More
